Analysts Offer Insights on Healthcare Companies: Forty Seven Inc (NASDAQ: FTSV) and uniQure NV (NASDAQ: QURE)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Forty Seven Inc (FTSVResearch Report) and uniQure NV (QUREResearch Report) with bullish sentiments.

Forty Seven Inc (FTSV)

Forty Seven Inc received a Buy rating and a $18 price target from Mizuho Securities analyst Mara Goldstein today. The company’s shares closed last Monday at $8, close to its 52-week low of $6.04.

Goldstein observed:

“We initiate coverage of FTSV with a Buy rating and $18 PT. We like the speed- to-market program for 5F9 (pivotal readout by 4Q20). We also like the pursuit of a novel mechanism in immuno-oncology, innate immunity via CD47. FTSV has cash into 2021 and readouts that should serve as valuation inflection points.”

According to TipRanks.com, Goldstein is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.2% and a 32.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, CytomX Therapeutics Inc, and Fate Therapeutics.

Forty Seven Inc has an analyst consensus of Strong Buy, with a price target consensus of $22.33, implying a 177.4% upside from current levels. In a report issued on August 27, Canaccord Genuity also reiterated a Buy rating on the stock with a $26 price target.

See today’s analyst top recommended stocks >>

uniQure NV (QURE)

Mizuho Securities analyst Difei Yang maintained a Buy rating on uniQure NV today and set a price target of $67. The company’s shares closed last Monday at $47.40.

Yang said:

“We see uniQure as one of the best gene therapy companies with a promising pipeline of indications. A pivotal trial of AMT-061 for the treatment of Hemophilia B is underway and we believe the product could be first and best- in-class, given strong efficacy and safety achieved in clinical trials so far. In Huntington’s disease, AMT-130 holds significant potential in a market where no disease-modifying therapies currently exist. Following a recent equity offering, uniQure is in solid financial position with a cash runway into 2022. Initiate at Buy/$67 PT.”

According to TipRanks.com, Yang is a 4-star analyst with an average return of 3.2% and a 38.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Audentes Therapeutics.

Currently, the analyst consensus on uniQure NV is a Strong Buy with an average price target of $99.40, implying an 113.3% upside from current levels. In a report issued on September 3, H.C. Wainwright also maintained a Buy rating on the stock with a $73 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.